The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This issue brief draws on features of the various existing Medicaid home and community-based services (HCBS) programs to identify key policy questions raised by initiatives to streamline Medicaid HCBS, ameliorate institutional bias, and improve administrative simplification.
During the Medicare open enrollment period, beneficiaries have the opportunity to enroll in a plan that provides Part D prescription drug coverage, either a stand-alone prescription drug plan (PDP) to supplement traditional Medicare, or a Medicare Advantage drug plan. This issue brief provides an overview of the 2016 PDP marketplace, focusing on key changes from 2015, based on analysis of data from the Centers for Medicare & Medicaid Services. It presents analysis of PDP availability, premiums, benefit design, and low-income subsidy plans.
About 656,000 people across the country were on state waiting lists for home and community-based services financed through Medicaid waivers in 2021, finds a new KFF analysis. But such waiting lists are an incomplete and often inaccurate measure that can both overstate and understate unmet need.
As winter approaches, a new KFF analysis finds that less than half (45%) of all nursing facility residents and less than a quarter of staff (22%) are up to date with their COVID-19 vaccinations. That is a sharp drop from the 87 percent of nursing facility residents and staff who completed their primary vaccination series.
Older adults have suffered more illness and death from covid-19 than any other group. How are they faring as the pandemic enters its third year? KFF’s Kaiser Health News (KHN) and The John A. Hartford Foundation explored that question in depth in a 90-minute interactive web event on Feb. 23, 2022.
This analysis provides the latest data about Medicare Part D enrollment, premiums, and cost sharing in 2022 and trends over time, including information about stand-alone prescription drug plans (PDPs) and Medicare Advantage prescription drug plans.
The Build Back Better Act (BBBA) includes a range of health and other proposals supported by President Biden, including a proposal to allow the federal government to negotiate the price of some prescription drugs covered under Medicare Part B (administered by physicians) and Medicare Part D (retail outpatient drugs). This brief illustrates the potential scope of the drug price negotiation proposal in the BBBA. This analysis is designed to highlight the types of Medicare-covered drugs that could be subject to negotiation, and which of the current top-spending drugs covered by Part B and Part D could be subject to price negotiation, and in what years, if the BBBA is enacted.
As Medicare Advantage continues to grow, a gradual but significant reshaping of the Medicare program is taking place. A new KFF analysis finds that nearly half of eligible Medicare beneficiaries – 28.4 million out of 58.6 million Medicare beneficiaries overall – are now enrolled in Medicare Advantage plans.
Our latest Vaccine Monitor survey finds that half of the public has heard either “a lot” or “some” about the newly-available bivalent COVID-19 boosters, and a third (32%) say they’ve already gotten it or intend to do so “as soon as possible.” It also updates parents’ vaccine intentions for their children, including those under 5.
Nearly 1 in 5 Parents of Children Under 5 Say Their Child Has Gotten a Vaccine, up from 7% in July, Though Half Say They Will “Definitely Not” Get Their Child Vaccinated Less than a month after the Food and Drug Administration authorized new COVID-19 booster shots that target both the omicron and original strains,…
© 2025 KFF